AI pioneer Dr. John E. Kelly III shares insights on building trust, improving data, and driving progress in AI-enabled neurological trials.
Discover how the new McDonald criteria use imaging biomarkers such as the Central Vein Sign (CVS) to make earlier, more accurate MS diagnosis
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Over 750 industry clinical trials have been initiated for...
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and...
The imaging clinical trials industry continues to grow in the face of unique challenges! To help you keep up, we’ve put together the top trends to...
Learn how QMENTA simplifies central vein detection in Multiple Sclerosis. Our solution automates protocol adherence, sequence recognition, and white...
Advance Parkinson’s research with QMENTA's Imaging Hub: cutting-edge imaging, biomarker insights, and cloud-based tools for early detection and...
Discover how the Central Vein Sign (CVS) may enhance diagnostic accuracy, advance research outcomes, and influence the McDonald criteria.